Ahmed Glaucoma Valve Implantation in Vitrectomized Eyes
Purpose. To evaluate the outcomes of Ahmed glaucoma valve (AGV) implantation in vitrectomized eyes. Materials and Methods. The medical records of 13 eyes that developed glaucoma due to emulsified silicon oil or neovascularization following pars plana vitrectomy and underwent AGV implantation were re...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2018/9572805 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561921515061248 |
|---|---|
| author | Nimet Yeşim Erçalık Serhat İmamoğlu |
| author_facet | Nimet Yeşim Erçalık Serhat İmamoğlu |
| author_sort | Nimet Yeşim Erçalık |
| collection | DOAJ |
| description | Purpose. To evaluate the outcomes of Ahmed glaucoma valve (AGV) implantation in vitrectomized eyes. Materials and Methods. The medical records of 13 eyes that developed glaucoma due to emulsified silicon oil or neovascularization following pars plana vitrectomy and underwent AGV implantation were retrospectively reviewed. The main outcome measures were intraocular pressure (IOP), best-corrected visual acuity (BCVA), number of antiglaucoma medications, and postoperative complications. Surgical success was defined as last IOP ≤21 mmHg or ≥6 mmHg and without loss of light perception. Results. The mean follow-up duration was 11.7 ± 5.5 (range, 6–23) months. The mean IOP before the AGV implantation was 37.9 ± 6.7 mmHg with an average of 3.5 ± 1.2 drugs. At the final visit, the mean IOP was 15.9 ± 4.6 mmHg (p=0.001) and the mean number of glaucoma medications decreased to 2.3 ± 1.3 (p=0.021). At the last visit, 11 eyes (84.4%) had stable or improved VA and one eye (7.7%) had a final VA of no light perception. Surgical success was achieved in 11 of the 13 eyes (84.4%). Postoperative complications were bleb encapsulation (69.2%), early hypotony (38.5%), hyphema (23.1%), decompression retinopathy (23.1%), choroidal detachment (15.4%), intraocular hemorrhage (7.7%), and late endophthalmitis (7.7%). One eye (7.7%) was enucleated because of late endophthalmitis. Conclusions. Despite complications necessitating medical and surgical interventions, vitrectomized eyes were effectively managed with AGV implantation. |
| format | Article |
| id | doaj-art-7bafc22c7bd04cf0a0cd985a0933bdee |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-7bafc22c7bd04cf0a0cd985a0933bdee2025-02-03T01:23:51ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/95728059572805Ahmed Glaucoma Valve Implantation in Vitrectomized EyesNimet Yeşim Erçalık0Serhat İmamoğlu1Haydarpaşa Numune Research and Training Hospital, Istanbul, TurkeyHaydarpaşa Numune Research and Training Hospital, Istanbul, TurkeyPurpose. To evaluate the outcomes of Ahmed glaucoma valve (AGV) implantation in vitrectomized eyes. Materials and Methods. The medical records of 13 eyes that developed glaucoma due to emulsified silicon oil or neovascularization following pars plana vitrectomy and underwent AGV implantation were retrospectively reviewed. The main outcome measures were intraocular pressure (IOP), best-corrected visual acuity (BCVA), number of antiglaucoma medications, and postoperative complications. Surgical success was defined as last IOP ≤21 mmHg or ≥6 mmHg and without loss of light perception. Results. The mean follow-up duration was 11.7 ± 5.5 (range, 6–23) months. The mean IOP before the AGV implantation was 37.9 ± 6.7 mmHg with an average of 3.5 ± 1.2 drugs. At the final visit, the mean IOP was 15.9 ± 4.6 mmHg (p=0.001) and the mean number of glaucoma medications decreased to 2.3 ± 1.3 (p=0.021). At the last visit, 11 eyes (84.4%) had stable or improved VA and one eye (7.7%) had a final VA of no light perception. Surgical success was achieved in 11 of the 13 eyes (84.4%). Postoperative complications were bleb encapsulation (69.2%), early hypotony (38.5%), hyphema (23.1%), decompression retinopathy (23.1%), choroidal detachment (15.4%), intraocular hemorrhage (7.7%), and late endophthalmitis (7.7%). One eye (7.7%) was enucleated because of late endophthalmitis. Conclusions. Despite complications necessitating medical and surgical interventions, vitrectomized eyes were effectively managed with AGV implantation.http://dx.doi.org/10.1155/2018/9572805 |
| spellingShingle | Nimet Yeşim Erçalık Serhat İmamoğlu Ahmed Glaucoma Valve Implantation in Vitrectomized Eyes Journal of Ophthalmology |
| title | Ahmed Glaucoma Valve Implantation in Vitrectomized Eyes |
| title_full | Ahmed Glaucoma Valve Implantation in Vitrectomized Eyes |
| title_fullStr | Ahmed Glaucoma Valve Implantation in Vitrectomized Eyes |
| title_full_unstemmed | Ahmed Glaucoma Valve Implantation in Vitrectomized Eyes |
| title_short | Ahmed Glaucoma Valve Implantation in Vitrectomized Eyes |
| title_sort | ahmed glaucoma valve implantation in vitrectomized eyes |
| url | http://dx.doi.org/10.1155/2018/9572805 |
| work_keys_str_mv | AT nimetyesimercalık ahmedglaucomavalveimplantationinvitrectomizedeyes AT serhatimamoglu ahmedglaucomavalveimplantationinvitrectomizedeyes |